Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04553666
PHASE2

Reducing Frailty for Older Cancer Survivors Using Supplements

Sponsor: University of Rochester

View on ClinicalTrials.gov

Summary

The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer

Official title: Reducing Frailty for Older Cancer Survivors Using Supplements (ReFOCUS): A Pilot Randomized Controlled Trial of the Feasibility, Safety, and Preliminary Effects of Epigallocatechin-3-Gallate (EGCG) in Pre-Frail and Frail Older Cancer Survivors

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2021-04-28

Completion Date

2023-08-31

Last Updated

2026-05-07

Healthy Volunteers

No

Interventions

DRUG

Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)

800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks

Locations (1)

University of Rochester

Rochester, New York, United States